期刊文献+

抗乙酰肝素酶单抗联合紫杉醇对肺癌A549增殖及侵袭的影响

Effect of anti-heparanase antibody combined with paclitaxel on the proliferation and invasiveness of A_(549) cells
下载PDF
导出
摘要 目的探讨抗乙酰肝素酶(heparanase,HPA)单抗联合紫杉醇对肺癌A549细胞的增殖及侵袭抑制作用。方法选用浓度梯度递增的抗HPA单抗和紫杉醇,单独或联合作用于A549细胞48 h后,采用MTT法检测细胞增殖,流式细胞仪检测细胞周期,细胞划痕试验、Transwell试验检测细胞侵袭,观察抗HPA单抗与紫杉醇对细胞增殖及转移的抑制作用。结果抗HPA单抗与紫杉醇联用后将抑制率从20%、31%、37%、45%、51%增大至52%、56%、60%、67%、77%。两药分别干预后细胞S期分别降低至4.7%、6.8%,联用后出现了36.5%的细胞凋亡期。在体外侵袭实验中抗HPA单抗、紫杉醇、紫杉醇联用抗HPA单抗使肺癌A549细胞侵袭能力分别下降(23.3±5.3)%、(63.3±3.9)%、(85.0±3.2)%。结论抗HPA单抗联合紫杉醇对肺癌A549细胞的增殖及侵袭能力的抑制作用比两药单用时更为显著。 Objective To investigate the effect of anti-heparanase antibody combined with paclitaxel on the proliferation and invasiveness of A549 cells.Methods Anti-HPA antibody and paclitaxel were used alone or in combination to treat A549 cells with increased dosages.After 48 hours,MTT was used to detect the cell proliferation,flow cytometry was applied to measure the cell cycle,and cell scratch test and Transwell were adopted to observe the cell invasiveness.Results The inhibition rate of paclitaxel combined with anti-HPA antibody increased from 20%,31%,37%,45% and 51% to 52%,56%,60%,67% and 77%,respectively, in a dosage-dependent manner.The S phase of cell cycle was reduced to 4.7% and 6.8% when A549 cells treated with paclitaxel and anti-HPA antibody,respectively.However,paclitaxel combined with anti-HPA antibody led to 36.5% apoptosis.In addition,the invasiveness of A549 cells decreased(23.3±5.3) %、(63.3 ±3.9) % and(85.0±3.2) % when treated with anti-HPA antibody,paclitaxel and paclitaxel combined with anti-HPA antibody,respectively.Conclusion Combination of anti-HPA antibody and paclitaxel for inhibition of A549 cells proliferation and invasiveness is more significant than only one drug used.
出处 《广东药学院学报》 CAS 2014年第3期341-345,共5页 Academic Journal of Guangdong College of Pharmacy
关键词 乙酰肝素酶 单抗 紫杉醇 heparanase monoclonal antibody paclitaxel
  • 相关文献

参考文献12

  • 1田辉,刘贤锡,王善政.肺癌组织中乙酰肝素酶与血管内皮生长因子-C的表达[J].中华外科杂志,2004,42(16):976-979. 被引量:9
  • 2宋永彬,王志康,柳立军,王会恩,周韶辉.乙酰肝素酶在非小细胞肺癌组织中的表达及临床意义[J].河北医药,2010,32(6):653-655. 被引量:2
  • 3BORGES S,DOPPLER H,PEREZ E A,et al. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis[J]. Breast Cancer Res, 2013,15 (2) : 66.
  • 4SIEGEL R,NAISHADHAM D,JEMAL A. Cancer statistics, 2013[J]. Cancer J Clin, 2013,63(1) :11-30.
  • 5SCHILLER J H, HARRINGTON D, BELANI C P, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [ J ]. N Engl J Med, 2002,346 (2) :92-98.
  • 6GUPTA N, HATOUM H, DY G K. First line treatment of advanced non-small-cell lung cancer specific focus on albumin bound paclitaxel [ J ]. Int J Nanomedicine, 2014,9 : 209-221.
  • 7SOCINSKI M A, OKAMOTO I, HON J K,et al. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer[ J]. Ann Oncol, 2013,24(9) : 2390-2396.
  • 8GRADISHAR W J, TJULANDIN S, DAVIDSON N, et al.Phase m trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer [ J ]. J Clin Oncol, 2005,23 ( 31 ) : 7794-7803.
  • 9HATA A, KATAKAMI N, TANAKA K, et al. Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated Non-squamous non-small cell lung [ J ] . Cancer Anticancer Res ,2014,34( 1 ) :275-281.
  • 10MCKENZIE E A. Heparanase: a target for drug discovery in cancer and inflammation [ J ]. Br J Pharmacol, 2007, 151(1) : 1-14.

二级参考文献38

  • 1田辉,刘贤锡,王善政.MMP-9、HPSE和VEGF-C蛋白表达在中老年人肺癌抗血管和抗淋巴管生成治疗中的意义[J].中国老年学杂志,2005,25(1):29-31. 被引量:3
  • 2Shinyo Y,Kodama J,Hongo A,et al.Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer.Ann Oncol,2003,14:1505-1510.
  • 3Sanderson RD,Yang Y,Suva LJ,et al.Heparan sulfate proteoglycans and heparanase-partners in osteolytic tumor growt and metastasis.Matrix Biol,2004,23:341-352.
  • 4Kurokawa H,Katsube K,Podyma KA,et al.Heparanase and tumor invasion patterns in human oral squamous cell carcinoma xenografts.Cancer Sci,2003,94:277-285.
  • 5Xiao Y,Kleef J,Shi X,et al.Heparanase expression in hepatocellular carcinoma and the cirrhotic liver.Hepato Res,2003,26:192-198.
  • 6Maxhimer JB,Quiros RM,Stewart R,et al.Heparanase-1 expression is associated with the metastatic potential obreast cancer.Surgery,2002,132:326-333.
  • 7Koliopanos A,Friess H,Kleeff J,et al.Heparanase expression in primary and metastatic pancreatic cancer.Cancer Res,2001,61:4655-4659.
  • 8Cohen E,Doweck I,Naroditsky I,et al.Heparanase is overexpressed in lung cancer and correlates inversely with patient survival[J].Cancer,2008;113(5):1004-11.
  • 9Crooke ST.Potential roles of antisense technology in cancer chemotherapy[J].Oncogene,2000;19(56):6651-9.
  • 10Uno F,Fujiwara T,Takata Y,et al.Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells[J].Cancer Res,2001;61(21):7855-60.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部